Patents Assigned to Universitatsmedizin der Johannes Gutenberg-Universitat Mainz
-
Publication number: 20240148825Abstract: The current disclosure provides methods and composition for treatment of autoimmune and inflammatory conditions, including systemic lupus erythematosus and antiphospholipid syndrome. Certain aspects of the disclosure are directed to methods for treatment of an autoimmune or inflammatory condition comprising administering a composition comprising a therapeutically effective amount of NAPc2 or NAPc2/proline. Further aspects include pharmaceutical compositions comprising NAPc2 or NAPc2/proline and, in some cases, one or more additional anti-inflammatory agents.Type: ApplicationFiled: June 9, 2022Publication date: May 9, 2024Applicant: UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZInventors: Wolfram RUF, Nadine MÜLLER-CALLEJA, Karl LACKNER, Julia WEINMANN-MENKE
-
Patent number: 11920194Abstract: This invention relates to methods for screening for a genotype for loss of antigen presentation via MHC class I in a subject and/or respectively detecting a subject's increased risk of resistance against immunotherapy such as against vaccination.Type: GrantFiled: June 1, 2018Date of Patent: March 5, 2024Assignees: BioNTech SE, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität MainzInventors: Ugur Sahin, Martin Suchan, Barbara Schrörs, Martin Löwer, Petra Oehm
-
Patent number: 11919951Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN6.Type: GrantFiled: February 7, 2022Date of Patent: March 5, 2024Assignees: Astellas Pharma Inc., TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität MainzInventors: Rita Mitnacht-Kraus, Stefan Wöll, Korden Walter, Özlem Türeci, Ugur Sahin
-
Patent number: 11732308Abstract: The invention generally relates to methods and compositions for the prediction of therapeutic efficacy of cancer treatments and the prognosis of cancer. The invention discloses markers that are associated with favorable and unfavorable outcomes, respectively, in certain cancer treatments and are useful as prognostic markers for cancer. Methods involving these markers are disclosed for predicting cancer therapy benefit and prognosing clinical outcome for cancer patients.Type: GrantFiled: December 23, 2020Date of Patent: August 22, 2023Assignees: Astellas Pharma Inc., TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GGMBHInventors: Ugur Sahin, Ozlem Tureci, Daniel Maurus
-
Patent number: 11713346Abstract: The present invention provides Claudin-18.2-specific immunoreceptors (T cell receptors and artificial T cell receptors (chimeric antigen receptors; CARs)) and T cell epitopes which are useful for immunotherapy.Type: GrantFiled: May 9, 2016Date of Patent: August 1, 2023Assignees: BioNTech Cell & Gene Therapies GmbH, TRON—Translationale Onkologie An Der Universitätsmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbHInventors: Ugur Sahin, Ozlem Tureci, Petra Oehm, Tana Omokoko, Andrea Breitkreuz, Karolina Anna Mroz, Lisa Hebich
-
Patent number: 11701413Abstract: The present invention relates to non-immunogenic RNA. This RNA forms the basis for the development of therapeutic agents for inducing tolerance towards an autoantigen and thus, for the treatment of autoimmune diseases.Type: GrantFiled: April 10, 2018Date of Patent: July 18, 2023Assignees: BioNTech SE, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbHInventors: Ugur Sahin, Sebastian Kreiter, Christina Krienke, Jutta Petschenka, Lena Mareen Kranz, Mustafa Diken
-
Patent number: 11559587Abstract: The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.Type: GrantFiled: September 23, 2019Date of Patent: January 24, 2023Assignees: TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH, BioNTech SEInventors: Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Mustafa Diken, Daniel Fritz, Martin Meng, Lena Mareen Kranz, Kerstin Reuter
-
Patent number: 11541127Abstract: The present invention provides anti-CLDN18.2 antibody-drug conjugates which are effective for treating and/or preventing cancer diseases associated with cells expressing CLDN18.2, including gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.Type: GrantFiled: April 13, 2016Date of Patent: January 3, 2023Assignees: Astellas Pharma, Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbHInventors: Ugur Sahin, Ozlem Tureci, Korden Walter, Maria Kreuzberg, Rita Mitnacht-Kraus, Fabrice Le Gall, Stefan Jacobs
-
Patent number: 11504419Abstract: The present invention relates to a patient-specific tumor treatment targeting individual expression patterns of tumor antigens, in particular shared tumor antigens, and individual tumor mutations. In one aspect, the present invention relates to a method for preventing or treating cancer in a patient comprising the steps of: (i) inducing a first immune response against one or more tumor antigens in the patient, and (ii) inducing a second immune response against one or more tumor antigens in the patient wherein the second immune response is specific for cancer specific somatic mutations present in cancer cells of the patient.Type: GrantFiled: October 26, 2018Date of Patent: November 22, 2022Assignees: BioNTech SE, TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbHInventors: Ugur Sahin, Claudia Paret, Kirsten Vormbrock, Christian Bender, Jan Diekmann
-
Patent number: 11492628Abstract: The present invention relates to stabilization of RNA, in particular mRNA, and an increase in mRNA translation. The present invention particularly relates to a modification of RNA, in particular in vitro-transcribed RNA, resulting in increased transcript stability and/or translation efficiency. According to the invention, it was demonstrated that certain sequences in the 3?-untranslated region (UTR) of an RNA molecule improve stability and translation efficiency.Type: GrantFiled: October 5, 2016Date of Patent: November 8, 2022Assignees: BioNTech SE, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbHInventors: Alexandra Orlandini Von Niessen, Stephanie Fesser, Britta Vallazza, Tim Beissert, Andreas Kuhn, Ugur Sahin, Marco Alexander Poleganov
-
Patent number: 11471522Abstract: The present invention relates to methods and compositions for stimulating an immune response. In particular, the present invention relates to immunostimulatory RNA molecules comprising sequences derived from an Influenza A virus nucleoprotein-encoding RNA molecule that act as adjuvants and/or immunostimulatory agents to enhance host immune responses.Type: GrantFiled: March 21, 2018Date of Patent: October 18, 2022Assignees: BIONTECH SE, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBHInventors: Mahjoub Bihi, Ugur Sahin, Mustafa Diken, Thorsten Klamp
-
Patent number: 11447825Abstract: A method for the detection of impaired responsiveness of CD4+ T-cells to regulatory T-cells (Treg), Treg resistance, by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1?) in activated CD4+ T-cells, in particular in patients suffering from relapsing remitting multiple sclerosis. The invention relates to an in vitro screening method for the detection of an autoimmune disease or a condition, comprising the steps of generating a functional gene expression profile by measuring the expression levels of peroxisome proliferator-activated receptor gamma coactivator 1-alpha, PPARGC1A (PGC-1?) in Treg-resistant CD4+ T-cells from patients suffering of an autoimmune disease or condition, and comparing the obtained gene expression profile with the expression profile from Treg-sensitive CD4+ T-cells from healthy controls.Type: GrantFiled: August 9, 2016Date of Patent: September 20, 2022Assignee: Universitätsmedizin der Johannes Gutenberg-Universität MainzInventors: Bettina Trinschek, Kazuki Satoh, Helmut Jonuleit
-
Patent number: 11384076Abstract: The present invention relates to small molecule compounds of formula (I) and their use as FLT3 inhibitors for the treatment of various diseases, such as acute myeloid leukemia (AML). The present invention further relates to methods of synthesizing the compounds and methods of treatment.Type: GrantFiled: August 9, 2018Date of Patent: July 12, 2022Assignees: UNIVERSITÄT REGENSBURG, UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZInventors: Siavosh Mahboobi, Andreas Sellmer, Herwig Pongratz, Bernardette Pilsl, Oliver Krämer, Thomas Kindler, Mandy Beyer
-
Patent number: 11337922Abstract: The present invention relates to lipid particles comprising at least one cationic lipid, at least one water-soluble therapeutically effective compound and RNA. Further, the present invention relates to a pharmaceutical composition comprising such particles. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the particles.Type: GrantFiled: May 25, 2021Date of Patent: May 24, 2022Assignees: BioN Tech SE, Tron—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg Universität Mainz GmbHInventors: Hossam Hefesha, Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Yves Hüsemann, Mustafa Diken, Kerstin Walzer
-
Patent number: 11318195Abstract: The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine. The RNA may encode a protein of interest, such as a pharmaceutically active protein. Furthermore, the present invention relates to pharmaceutical products, comprising said RNA polyplex formulations for parenteral application to humans or to animals. The present invention relates as well to manufacturing of such pharmaceutical products, comprising, optionally, steps of sterile filtration, freezing and dehydration.Type: GrantFiled: July 14, 2017Date of Patent: May 3, 2022Assignees: BIONTECH SE, TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBHInventors: Ugur Sahin, Heinrich Haas, Annette Vogel, Daniel Zucker, Stephanie Erbar, Kerstin Walzer, Anne Schlegel, Sebastian Hörner, Sebastian Kreiter, Mustafa Diken, Jorge Moreno Herrero
-
Patent number: 11279757Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN6 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN6.Type: GrantFiled: September 5, 2018Date of Patent: March 22, 2022Assignees: Astellas Pharma Inc., TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbhInventors: Rita Mitnacht-Kraus, Stefan Wöll, Korden Walter, Özlem Türeci, Ugur Sahin
-
Patent number: 11248264Abstract: The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.Type: GrantFiled: July 2, 2020Date of Patent: February 15, 2022Assignees: TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH, BioNTech SEInventors: Ugur Sahin, Sebastian Kreiter, Mustafa Diken, Jan Diekmann, Michael Koslowski, Cedrik Britten, John Christopher Castle, Martin Löwer, Bernhard Renard, Tana Omokoko, Johannes Hendrikus De Graaf
-
Patent number: 11222711Abstract: The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether modifications in peptides or polypeptides such as tumor-associated neoantigens are immunogenic or not. The methods of the invention are useful, in particular, for the provision of vaccines which are specific for a patient's tumor and, thus, in the context of personalized cancer vaccines.Type: GrantFiled: May 7, 2014Date of Patent: January 11, 2022Assignees: BioNTech SE, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbHInventors: Ugur Sahin, Arbel David Tadmor, John Christopher Castle, Sebastian Boegel, Martin Löwer
-
Patent number: 11168337Abstract: The present invention embraces a RNA replicon that can be replicated by a replicase of alphavirus origin. The RNA replicon comprises sequence elements required for replication by the replicase, but these sequence elements do not encode any protein or fragment thereof, such as an alphavirus non-structural protein or fragment thereof. Thus, in the RNA replicon according to the invention, sequence elements required for replication by the replicase and protein-coding region(s) are uncoupled. According to the present invention the uncoupling is achieved by the removal of at least one initiation codon compared to a native alphavirus genomic RNA. In particular, the RNA replicon comprises a 5? replication recognition sequence, wherein the 5? replication recognition sequence is characterized in that it comprises the removal of at least one initiation codon compared to a native alphavirus 5? replication recognition sequence.Type: GrantFiled: March 13, 2017Date of Patent: November 9, 2021Assignees: Moniech RNA Pharmecenticais GmbH, TRON—Translationale Onkologie An Der Universitätsmedizín Der Johannes Gutenberg-Universität Mainz Gemeinnützige GmbHInventors: Tim Beissert, Ugur Sahin, Mario Perkovic
-
Patent number: 11045418Abstract: The present invention relates to lipid particles comprising at least one cationic lipid, at least one water-soluble therapeutically effective compound and RNA. Further, the present invention relates to a pharmaceutical composition comprising such particles. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the particles.Type: GrantFiled: March 30, 2016Date of Patent: June 29, 2021Assignees: BioNTech RNA Pharmaceuticals GmbH, Tron-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat MainzInventors: Hossam Hefesha, Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Yves Hüsemann, Mustafa Diken, Kerstin Walzer